While future studies aimed at answering this question are likely to provide interesting insights into SUMO function and regulation, the predominance of SUMO2 in tumor cells makes it the ideal SUMO paralog target for anti-tumor therapeutics. This evidence concerns the gene SUMO2 and neoplasm.